Skip to Main Content

Author Details

Kris C Wood
Duke University
2005
65
25
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37573235Sublethal engagement of apoptotic pathways in residual cancer.Trends Cell Biol2024
36711936MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i>-mutant non-small cell lung cancer through covalent inhibition of KEAP1.bioRxiv2023
37749245Hyperactivation of oncogenic driver pathways as a precision therapeutic strategy.Nat Genet2023
37786671Integrative <i>PTEN</i> Enhancer Discovery Reveals a New Model of Enhancer Organization.bioRxiv2023
37695916Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13.Proc Natl Acad Sci U S A2023
37493631CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer.Mol Cancer Res2023
37284233Endogenous and imposed determinants of apoptotic vulnerabilities in cancer.Trends Cancer2023
37040401ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1.Proc Natl Acad Sci U S A2023
36918588Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis.Nat Commun2023
34737198Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in <i>H/NRAS<sup>Q61X</sup></i> Mutant Rhabdomyosarcoma.Mol Cancer Ther2022
35353542Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.Sci Transl Med2022
35536676A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models.J Clin Invest2022
35668193P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.Nat Cancer2022
36438856A high throughput proliferation and cytotoxicity assay for co-cultured isogenic cell lines.MethodsX2022
36274097Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies.NPJ Precis Oncol2022
35926468Cancer genes disfavoring T cell immunity identified via integrated systems approach.Cell Rep2022
36321262Challenges and Emerging Opportunities for Targeting mTOR in Cancer.Cancer Res2022
35247914Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.Mol Cancer Ther2022
35332333Drivers of intrinsic resistance.Nat Chem Biol2022
34215753Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates.NPJ Breast Cancer2021
34706244ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells.Cell Rep2021
34535683Author Correction: Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates.NPJ Breast Cancer2021
34533995Massively parallel quantification of phenotypic heterogeneity in single-cell drug responses.Sci Adv2021
32203462Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer.Nat Genet2020
31748414Evolved resistance to partial GAPDH inhibition results in loss of the Warburg effect and in a different state of glycolysis.J Biol Chem2020
31988312Overcoming MCL-1-driven adaptive resistance to targeted therapies.Nat Commun2020
32826232The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.Cancer Discov2020
32694612Author Correction: Cooperative nutrient accumulation sustains growth of mammalian cells.Sci Rep2020
32553168Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.Cell Rep2020
31136607Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.PLoS One2019
31517048Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models.Sci Adv2019
31253832Label propagation defines signaling networks associated with recurrently mutated cancer genes.Sci Rep2019
31391551PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers.Oncogene2019
30773463Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity.Cell Metab2019
29709255Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers.Trends Cancer2018
30158527Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity.Nat Commun2018
29931016An acoustofluidic trap and transfer approach for organizing a high density single cell array.Lab Chip2018
30799887Bayesian Approximate Kernel Regression with Variable Selection.J Am Stat Assoc2018
30323337Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers.Nat Commun2018
29700304Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors.Nat Commun2018
28746882A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Cell Rep2017
28425914Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection.Elife2017
28123073Suppressing oncogenic transcription with a little healthy competition.Sci Transl Med2017
29212027Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.Cell Rep2017
28593995Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.Nat Commun2017
27050525ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer.Cell Rep2016
27738492Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes.Genes Cancer2016
27928023An EXITS strategy for decreasing cancer risk in women.Sci Transl Med2016
27974663PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.Sci Transl Med2016
27265611An Automated High-throughput Array Microscope for Cancer Cell Mechanics.Sci Rep2016
  • 1 - 50 of 65

Recommended Authors

Mark A Murakami
Dana-Farber Cancer Institute
Career Start Year 2015
Number of shared co-authors 6
Sahil Seth
The University of Texas MD Anderson Cancer Center
Career Start Year 2014
Number of shared co-authors 2
Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 0
Daniel J McGrail
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Career Start Year 2012
Number of shared co-authors 0
Victor Olivas
University of California san francisco
Career Start Year 2012
Number of shared co-authors 3
Brian J Capaldo
Center for Cancer Research, National Cancer Institute
Career Start Year 2012
Number of shared co-authors 1
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 8
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 2
Guo Chen
China Pharmaceutical University
Career Start Year 2009
Number of shared co-authors 3
John Paul Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 1
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 3
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 4
Jonathan R Dry
Present Address: Tempus Labs Inc.
Career Start Year 2003
Number of shared co-authors 3
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 1
Justin Cidado
Oncology R&D
Career Start Year 2003
Number of shared co-authors 0
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 3
Eric A Collisson
University of California san francisco
Career Start Year 1999
Number of shared co-authors 4
Mathew J Garnett
Wellcome Sanger Institute
Career Start Year 1998
Number of shared co-authors 10
Charles Swanton
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 6
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 9
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 0
Andrei Goga
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 2
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 5
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 14
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 9
Lori S Hart
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Career Start Year 1987
Number of shared co-authors 3
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 3
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 5
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 13

Collaborators

Kevin H Lin
Duke University
Co-authored papers 15
Gray R Anderson
Duke University
Co-authored papers 13
Peter S Winter
Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School
Co-authored papers 12
Lorin Crawford
Center for Computational Molecular Biology, Brown University
Co-authored papers 6
Katherine R Singleton
Duke University
Co-authored papers 6
Merve Cakir
Quantitative Biosciences Institute (QBI), University of California san francisco
Co-authored papers 6
Jacob P Hoj
Duke University
Co-authored papers 6
David M Sabatini
Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology
Co-authored papers 5
Donald P McDonnell
Co-authored papers 5
Jason W Locasale
Duke University
Co-authored papers 5
Christopher F Bassil
Duke University School of Medicine Durham
Co-authored papers 5
Hazel X Ang
Duke University School of Medicine
Co-authored papers 4
Min Lu
Shangrao Hospital Affiliated to Nanchang University
Co-authored papers 4
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Co-authored papers 4
Abigail Xie
Duke University
Co-authored papers 4
Ashutosh Chilkoti
Duke University
Co-authored papers 4
Yeong-Ran Ahn
Duke University
Co-authored papers 3
Emanuel F Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 3
Mariaelena Pierobon
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 3
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Co-authored papers 3
Antoine Forget (CM4AI)
University of California San Francisco
Co-authored papers 3
Gaetano Sodaro
Universite Paris Cite, INSERM, CNRS
Co-authored papers 2
Terry Hyslop
Co-authored papers 2
Patrick Auberger
Universite Cote d'Azur, INSERM U5
Co-authored papers 2
David A Rizzieri
Duke University Medical Center
Co-authored papers 2
Xinghai Li
Duke University
Co-authored papers 2
Reinaldo Dal Bello
Universite Paris Cite, INSERM, CNRS
Co-authored papers 2
Nina Fenouille
Universite Paris Cite, INSERM, CNRS
Co-authored papers 2
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Co-authored papers 2
Timothy S Pardee
Comprehensive Cancer Center of Wake Forest Baptist Health, Medical Center Boulevard
Co-authored papers 2
Release 1.2